- Smilow Multiple Myeloma and Gammopathies ProgramSmilow Cancer Hospital at North Haven6 Devine StreetNorth Haven, CT 06473
Terri Parker, MD
Biography
Terri Parker, MD, is a hematologist and assistant medical director at the Smilow Cancer Hospital Care Center in North Haven.
Dr. Parker treats patients with plasma cell dyscrasias, including multiple myeloma, and related diseases such as AL amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), plasma cell leukemia, smoldering multiple myeloma, and Waldenstrom’s macroglobulinemia.
“These are all disorders where the primary abnormality is in the plasma cell. Plasma cells are a type of white blood cell,” Dr. Parker explains. “I was drawn to hematology because it isn’t just one organ system involved. It touches on everything. And I love the continuity of care it provides as I get to know my patients.”
Dr. Parker says she is encouraged by the advances that have been made in recent years in terms of new therapies for conditions like multiple myeloma. “Right now, there isn’t a cure for multiple myeloma, but it’s very treatable,” she says.
She says she also enjoys the team aspect of her job. “It isn’t just me a patient sees but there is a whole team caring for the patient including advanced practice providers such as physician’s assistants, other myeloma specialists, a dedicated pharmacist, social worker, and a nutritionist. There is also a support group for patients,” she says.
Dr. Parker’s research interests focus on novel therapies and drug combinations to improve care for patients with AL amyloidosis, newly diagnosed and relapsed refractory multiple myeloma.
Titles
- Assistant Professor of Medicine (Hematology)
- Assistant Medical Director, Smilow Cancer Hospital, North Haven
Education & Training
- FellowshipYale University School of Medicine (2012)
- FellowshipUniversity of Connecticut Health Center (2009)
- ResidencyUniversity of Connecticut Health Center (2008)
- MDSt. George's University School of Medicine Grenada (2005)
- BSUniversity of Pittsburgh (2001)
Additional Information
- David S. Fischer Teaching Award for Outstanding Faculty Teaching and Mentoring of Fellows in Medical Oncology: (2016)
- Letter of Recognition from Evaluation and Promotions Committee: University of Connecticut (2006)
- AB of Internal Medicine, Medical Oncology (2013, recertified: 2015)
- AB of Internal Medicine, Hematology (Internal Medicine) (2012)
- American Society of Hematology (2018 - 2021): Chosen as an inaugural American Society of Hematology (ASH) Ambassador. This was a formal volunteer role to support recruitment and retention of trainees to hematology and to ASH through promotion of ASH’s career development and training programs.
- Faculty Advisory Council, Yale University School of Medicine (2015 - 2017): The purpose of the Faculty Advisor Council is to provide a forum for a diverse group of representatives to bring new ideas and concerns from a broad range of faculty to the Dean’s office. I served a two year term representing the sections of hematology/medical oncology.
- Protocol Review Committee, Yale Cancer Center, Yale University School of Medicine (2015 - Present): Member of the scientific protocol review committee for the cancer center. The committee is responsible for reviewing the scientific merit, priorities, and progress of Yale Cancer Center clinical research trials.
- Song J, Deshpande S, Chang Y, Chiang C, Ahn J, Lessa A, Soni A, Gonzales A, Lee P, Chang Y, Parker T, Kwan J, Chi K, Nanna M. The Association between Glucagon-like Peptide-1 Receptor Agonist and Major Adverse Cardiac and Cerebrovascular Events in Monoclonal Gammopathy of Undetermined Significance: A Propensity-Score Analysis. Blood 2024, 144: 6869. DOI: 10.1182/blood-2024-194867.
- Browning S, Li F, Theprungsirikul P, Parker T, Bar N, Giri S, Anderson T, Stevens E, Gorshein E, Sabbath K, Wei C, Ali S, Witt D, Persico J, Talsania A, Rahmat L, Kidwai W, Legare R, LaSala J, Austin M, Neparidze N. Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma. Blood 2024, 144: 7831. DOI: 10.1182/blood-2024-204150.
- Hagen P, Sidana S, Parker T, Walker B, Sanchorawala V, Zonder J, Kourelis T, D'Souza A, Landau H, Rosenthal A, Hoering A, Ailawadhi S, Orlowski R. A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis. Blood 2024, 144: 3309.1-3309.1. DOI: 10.1182/blood-2024-208227.
- Parker T, Rosenthal A, Sanchorawala V, Landau H, Campagnaro E, Kapoor P, Neparidze N, Girnius S, Hagen P, Scott E, Hoering A, Durie B, Orlowski R. Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702). Blood 2024, 144: 3378-3378. DOI: 10.1182/blood-2024-208341.
- Theprungsirikul P, Yu M, Liu Y, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. P-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s92-s93. DOI: 10.1016/s2152-2650(24)01991-8.
- Muradashvili T, Yu M, Browning S, Bar N, Gorshein E, Parker T, Neparidze N. Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis. Leukemia 2024, 38: 2281-2283. PMID: 39164408, DOI: 10.1038/s41375-024-02380-x.
- Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.
- Hagen P, Sidana S, Parker T, Walker B, Hoering A, Sanchorawala V, Zonder J, Kourelis T, D'Souza A, Landau H, Rosenthal A, Ailawadhi S, Orlowski R. A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis. Journal Of Clinical Oncology 2024, 42: tps7575-tps7575. DOI: 10.1200/jco.2024.42.16_suppl.tps7575.
- Hagen P, Hoering A, Sidana S, Parker T, Walker B, Sanchorawala V, Zonder J, Kourelis T, D’Souza A, Landau H, Rosenthal A, Ailawadhi S, Z. R. A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed by Autologous Stem Cell Transplant or DARA-VCD Consolidation and Daratumumab Maintenance in patients with Newly Diagnosed AL Amyloidosis PA145 (#114). 2024 DOI: 10.26226/m.65f9bf89e6f73964e1d4eb32.
- Liu Y, Kywe B, Crawford L, Lora F, Bar N, Browning S, Gorshein E, Parker T, Neparidze N. Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience. Blood 2021, 138: 1635. DOI: 10.1182/blood-2021-146619.
- Dosani T, Poteraj A, Parker T, Bar N, Browning S, Gorshein E, Anderson T, Insogna K, Neparidze N. Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center. Blood 2021, 138: 4756. DOI: 10.1182/blood-2021-147466.
- Patel K, Parker T, Di M, Bar N, Huntington S, Giri S. Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma. Blood 2020, 136: 51-52. DOI: 10.1182/blood-2020-141972.
- Parker T, Rosenthal A, Sanchorawala V, Landau H, Campagnaro E, Kapoor P, Neparidze N, Hagen P, Sarosiek S, Scott E, Hoering A, Durie B, Usmani S, Orlowski R. A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808). Blood 2020, 136: 20-21. DOI: 10.1182/blood-2020-143180.
- Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder JA, Faber E, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, Wagner LI, Rajkumar SV. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. The Lancet Oncology 2020, 21: 1317-1330. PMID: 32866432, PMCID: PMC7591827, DOI: 10.1016/s1470-2045(20)30452-6.
- Kumar S, Jacobus S, Cohen A, Weiss M, Callander N, Singh A, Parker T, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder J, Faber E, Lonial S, Richardson P, Orlowski R, Wagner L, Rajkumar S. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial. Journal Of Clinical Oncology 2020, 38: lba3-lba3. DOI: 10.1200/jco.2020.38.18_suppl.lba3.
- Gavriatopoulou M, Chari A, Chen C, Bahlis N, Vogl DT, Jakubowiak A, Dingli D, Cornell RF, Hofmeister CC, Siegel D, Berdeja JG, Reece D, White D, Lentzsch S, Gasparetto C, Huff CA, Jagannath S, Baz R, Nooka AK, Richter J, Abonour R, Parker TL, Yee AJ, Moreau P, Lonial S, Tuchman S, Weisel KC, Mohty M, Choquet S, Unger TJ, Li K, Chai Y, Li L, Shah J, Shacham S, Kauffman MG, Dimopoulos MA. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia 2020, 34: 2430-2440. PMID: 32094461, PMCID: PMC7449872, DOI: 10.1038/s41375-020-0756-6.
- Browning S, Parker T, Bar N, Seropian S, Lee A, Anderson T, Neparidze N. Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center. Blood 2019, 134: 5569. DOI: 10.1182/blood-2019-130134.
- Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. The New England Journal Of Medicine 2019, 381: 727-738. PMID: 31433920, DOI: 10.1056/NEJMoa1903455.
- Nair S, Sng J, Boddupalli CS, Seckinger A, Chesi M, Fulciniti M, Zhang L, Rauniyar N, Lopez M, Neparidze N, Parker T, Munshi NC, Sexton R, Barlogie B, Orlowski R, Bergsagel L, Hose D, Flavell RA, Mistry PK, Meffre E, Dhodapkar MV. Antigen-mediated regulation in monoclonal gammopathies and myeloma. JCI Insight 2018, 3: e98259. PMID: 29669929, PMCID: PMC5931125, DOI: 10.1172/jci.insight.98259.
- Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2018, 36: 859-866. PMID: 29381435, PMCID: PMC6905485, DOI: 10.1200/JCO.2017.75.5207.
- Foss FM, Parker T. A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma. The Oncologist 2018, 23: 397-e30. PMID: 29438091, PMCID: PMC5896711, DOI: 10.1634/theoncologist.2017-0658.
- Kini Bailur J, Mehta S, Zhang L, Neparidze N, Parker T, Bar N, Anderson T, Xu ML, Dhodapkar KM, Dhodapkar MV. Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy. Blood Advances 2017, 1: 2343-2347. PMID: 29296884, PMCID: PMC5729633, DOI: 10.1182/bloodadvances.2017012732.
- Branagan A, Duffy E, Parker T, Seropian S, Foster C, Zhang L, Verma R, Gan G, Zelterman D, Brandt D, Kortmansky J, Witt D, Dhodapkar M. 2168. Journal Of Clinical And Translational Science 2017, 1: 31-32. PMCID: PMC6799516, DOI: 10.1017/cts.2017.118.
- Branagan AR, Duffy E, Albrecht RA, Cooper DL, Seropian S, Parker TL, Gan G, Li F, Zelterman D, Boddupalli CS, Zhang L, Verma R, Ferencz TM, Dhodapkar MV. Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial. Clinical Lymphoma Myeloma & Leukemia 2017, 17: 296-304.e2. PMID: 28343904, PMCID: PMC5413398, DOI: 10.1016/j.clml.2017.02.025.
- Branagan A, Duffy E, Parker T, Seropian S, Foster C, Zhang L, Verma R, Zelterman D, Gan G, Brandt D, Kortmansky J, Witt D, Ferencz T, Dhodapkar M. Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial. Blood 2016, 128: 2139. DOI: 10.1182/blood.v128.22.2139.2139.
- Foss F, Parker T, Li A. Impact of leucovorin on mucositis and skin reactions in pts with peripheral t-cell lymphoma (PTCL) and cutaneous t-cell lymphoma (CTCL) treated with pralatrexate. Journal Of Clinical Oncology 2016, 34: 7558-7558. DOI: 10.1200/jco.2016.34.15_suppl.7558.
- Barmettler S, Nowak RJ, Parker T, Price C. Previously undiagnosed fatal familial haemophagocytic lymphohistiocytosis in a 24-year-old woman. BMJ Case Reports 2016, 2016: bcr2015213698. PMID: 26903364, PMCID: PMC4769444, DOI: 10.1136/bcr-2015-213698.
- Branagan A, Duffy E, Boddupall C, Albrecht R, Zhang L, Verma R, Cooper D, Seropian S, Parker T, Yao X, Ferencz T, Dhodapkar M. Fluzone® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders. Blood 2015, 126: 3058. DOI: 10.1182/blood.v126.23.3058.3058.
- Bar N, Parker TL, Dhodapkar MV. Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart. Journal Of Clinical Oncology 2015, 33: 3689-3690. PMID: 26371139, DOI: 10.1200/jco.2015.63.2224.
- Odell ID, Zeidan AM, Parker TL, Colegio OR, Subtil A. Leukaemic vasculitis with myelodysplastic syndrome. The Lancet 2015, 386: 501-502. PMID: 26251396, DOI: 10.1016/s0140-6736(15)61165-5.
- Brahmandam AS, Brownson K, Skrip L, Parker T, Indes J, Sarac T, Dardik A, Chaar CI. Management of isolated calf vein thrombosis in cancer patients. Vascular 2015, 24: 64-69. PMID: 25957344, DOI: 10.1177/1708538115584726.
- Parker T, Barbarotta L, Foss F. Pralatrexate: treatment of T-cell non-Hodgkins lymphoma. Future Oncology 2012, 9: 21-29. PMID: 23252560, DOI: 10.2217/fon.12.168.
- Parker TL, Cooper DL, Seropian SE, Bolognia JL. Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant. Bone Marrow Transplantation 2012, 48: 646-650. PMID: 23165491, DOI: 10.1038/bmt.2012.218.
- Parker T, Barbarotta L, Girardi M, Foss F. Cutaneous Toxicity Associated with Pralatrexate in Cutaneous and Peripheral T-Cell Lymphoma. Blood 2012, 120: 3660. DOI: 10.1182/blood.v120.21.3660.3660.
- Parker TL, Strout MP. Chronic lymphocytic leukemia: prognostic factors and impact on treatment. Discovery Medicine 2011, 11: 115-23. PMID: 21356166.
- Smilow Multiple Myeloma and Gammopathies ProgramSmilow Cancer Hospital at North Haven6 Devine StreetNorth Haven, CT 06473
Biography
Terri Parker, MD, is a hematologist and assistant medical director at the Smilow Cancer Hospital Care Center in North Haven.
Dr. Parker treats patients with plasma cell dyscrasias, including multiple myeloma, and related diseases such as AL amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), plasma cell leukemia, smoldering multiple myeloma, and Waldenstrom’s macroglobulinemia.
“These are all disorders where the primary abnormality is in the plasma cell. Plasma cells are a type of white blood cell,” Dr. Parker explains. “I was drawn to hematology because it isn’t just one organ system involved. It touches on everything. And I love the continuity of care it provides as I get to know my patients.”
Dr. Parker says she is encouraged by the advances that have been made in recent years in terms of new therapies for conditions like multiple myeloma. “Right now, there isn’t a cure for multiple myeloma, but it’s very treatable,” she says.
She says she also enjoys the team aspect of her job. “It isn’t just me a patient sees but there is a whole team caring for the patient including advanced practice providers such as physician’s assistants, other myeloma specialists, a dedicated pharmacist, social worker, and a nutritionist. There is also a support group for patients,” she says.
Dr. Parker’s research interests focus on novel therapies and drug combinations to improve care for patients with AL amyloidosis, newly diagnosed and relapsed refractory multiple myeloma.
Titles
- Assistant Professor of Medicine (Hematology)
- Assistant Medical Director, Smilow Cancer Hospital, North Haven
Education & Training
- FellowshipYale University School of Medicine (2012)
- FellowshipUniversity of Connecticut Health Center (2009)
- ResidencyUniversity of Connecticut Health Center (2008)
- MDSt. George's University School of Medicine Grenada (2005)
- BSUniversity of Pittsburgh (2001)
Additional Information
- David S. Fischer Teaching Award for Outstanding Faculty Teaching and Mentoring of Fellows in Medical Oncology: (2016)
- Letter of Recognition from Evaluation and Promotions Committee: University of Connecticut (2006)
- AB of Internal Medicine, Medical Oncology (2013, recertified: 2015)
- AB of Internal Medicine, Hematology (Internal Medicine) (2012)
- American Society of Hematology (2018 - 2021): Chosen as an inaugural American Society of Hematology (ASH) Ambassador. This was a formal volunteer role to support recruitment and retention of trainees to hematology and to ASH through promotion of ASH’s career development and training programs.
- Faculty Advisory Council, Yale University School of Medicine (2015 - 2017): The purpose of the Faculty Advisor Council is to provide a forum for a diverse group of representatives to bring new ideas and concerns from a broad range of faculty to the Dean’s office. I served a two year term representing the sections of hematology/medical oncology.
- Protocol Review Committee, Yale Cancer Center, Yale University School of Medicine (2015 - Present): Member of the scientific protocol review committee for the cancer center. The committee is responsible for reviewing the scientific merit, priorities, and progress of Yale Cancer Center clinical research trials.
- Song J, Deshpande S, Chang Y, Chiang C, Ahn J, Lessa A, Soni A, Gonzales A, Lee P, Chang Y, Parker T, Kwan J, Chi K, Nanna M. The Association between Glucagon-like Peptide-1 Receptor Agonist and Major Adverse Cardiac and Cerebrovascular Events in Monoclonal Gammopathy of Undetermined Significance: A Propensity-Score Analysis. Blood 2024, 144: 6869. DOI: 10.1182/blood-2024-194867.
- Browning S, Li F, Theprungsirikul P, Parker T, Bar N, Giri S, Anderson T, Stevens E, Gorshein E, Sabbath K, Wei C, Ali S, Witt D, Persico J, Talsania A, Rahmat L, Kidwai W, Legare R, LaSala J, Austin M, Neparidze N. Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma. Blood 2024, 144: 7831. DOI: 10.1182/blood-2024-204150.
- Hagen P, Sidana S, Parker T, Walker B, Sanchorawala V, Zonder J, Kourelis T, D'Souza A, Landau H, Rosenthal A, Hoering A, Ailawadhi S, Orlowski R. A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis. Blood 2024, 144: 3309.1-3309.1. DOI: 10.1182/blood-2024-208227.
- Parker T, Rosenthal A, Sanchorawala V, Landau H, Campagnaro E, Kapoor P, Neparidze N, Girnius S, Hagen P, Scott E, Hoering A, Durie B, Orlowski R. Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702). Blood 2024, 144: 3378-3378. DOI: 10.1182/blood-2024-208341.
- Theprungsirikul P, Yu M, Liu Y, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. P-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s92-s93. DOI: 10.1016/s2152-2650(24)01991-8.
- Muradashvili T, Yu M, Browning S, Bar N, Gorshein E, Parker T, Neparidze N. Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis. Leukemia 2024, 38: 2281-2283. PMID: 39164408, DOI: 10.1038/s41375-024-02380-x.
- Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.
- Hagen P, Sidana S, Parker T, Walker B, Hoering A, Sanchorawala V, Zonder J, Kourelis T, D'Souza A, Landau H, Rosenthal A, Ailawadhi S, Orlowski R. A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis. Journal Of Clinical Oncology 2024, 42: tps7575-tps7575. DOI: 10.1200/jco.2024.42.16_suppl.tps7575.
- Hagen P, Hoering A, Sidana S, Parker T, Walker B, Sanchorawala V, Zonder J, Kourelis T, D’Souza A, Landau H, Rosenthal A, Ailawadhi S, Z. R. A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed by Autologous Stem Cell Transplant or DARA-VCD Consolidation and Daratumumab Maintenance in patients with Newly Diagnosed AL Amyloidosis PA145 (#114). 2024 DOI: 10.26226/m.65f9bf89e6f73964e1d4eb32.
- Liu Y, Kywe B, Crawford L, Lora F, Bar N, Browning S, Gorshein E, Parker T, Neparidze N. Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience. Blood 2021, 138: 1635. DOI: 10.1182/blood-2021-146619.
- Dosani T, Poteraj A, Parker T, Bar N, Browning S, Gorshein E, Anderson T, Insogna K, Neparidze N. Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center. Blood 2021, 138: 4756. DOI: 10.1182/blood-2021-147466.
- Patel K, Parker T, Di M, Bar N, Huntington S, Giri S. Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma. Blood 2020, 136: 51-52. DOI: 10.1182/blood-2020-141972.
- Parker T, Rosenthal A, Sanchorawala V, Landau H, Campagnaro E, Kapoor P, Neparidze N, Hagen P, Sarosiek S, Scott E, Hoering A, Durie B, Usmani S, Orlowski R. A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808). Blood 2020, 136: 20-21. DOI: 10.1182/blood-2020-143180.
- Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder JA, Faber E, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, Wagner LI, Rajkumar SV. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. The Lancet Oncology 2020, 21: 1317-1330. PMID: 32866432, PMCID: PMC7591827, DOI: 10.1016/s1470-2045(20)30452-6.
- Kumar S, Jacobus S, Cohen A, Weiss M, Callander N, Singh A, Parker T, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder J, Faber E, Lonial S, Richardson P, Orlowski R, Wagner L, Rajkumar S. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial. Journal Of Clinical Oncology 2020, 38: lba3-lba3. DOI: 10.1200/jco.2020.38.18_suppl.lba3.
- Gavriatopoulou M, Chari A, Chen C, Bahlis N, Vogl DT, Jakubowiak A, Dingli D, Cornell RF, Hofmeister CC, Siegel D, Berdeja JG, Reece D, White D, Lentzsch S, Gasparetto C, Huff CA, Jagannath S, Baz R, Nooka AK, Richter J, Abonour R, Parker TL, Yee AJ, Moreau P, Lonial S, Tuchman S, Weisel KC, Mohty M, Choquet S, Unger TJ, Li K, Chai Y, Li L, Shah J, Shacham S, Kauffman MG, Dimopoulos MA. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia 2020, 34: 2430-2440. PMID: 32094461, PMCID: PMC7449872, DOI: 10.1038/s41375-020-0756-6.
- Browning S, Parker T, Bar N, Seropian S, Lee A, Anderson T, Neparidze N. Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center. Blood 2019, 134: 5569. DOI: 10.1182/blood-2019-130134.
- Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. The New England Journal Of Medicine 2019, 381: 727-738. PMID: 31433920, DOI: 10.1056/NEJMoa1903455.
- Nair S, Sng J, Boddupalli CS, Seckinger A, Chesi M, Fulciniti M, Zhang L, Rauniyar N, Lopez M, Neparidze N, Parker T, Munshi NC, Sexton R, Barlogie B, Orlowski R, Bergsagel L, Hose D, Flavell RA, Mistry PK, Meffre E, Dhodapkar MV. Antigen-mediated regulation in monoclonal gammopathies and myeloma. JCI Insight 2018, 3: e98259. PMID: 29669929, PMCID: PMC5931125, DOI: 10.1172/jci.insight.98259.
- Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2018, 36: 859-866. PMID: 29381435, PMCID: PMC6905485, DOI: 10.1200/JCO.2017.75.5207.
- Foss FM, Parker T. A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma. The Oncologist 2018, 23: 397-e30. PMID: 29438091, PMCID: PMC5896711, DOI: 10.1634/theoncologist.2017-0658.
- Kini Bailur J, Mehta S, Zhang L, Neparidze N, Parker T, Bar N, Anderson T, Xu ML, Dhodapkar KM, Dhodapkar MV. Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy. Blood Advances 2017, 1: 2343-2347. PMID: 29296884, PMCID: PMC5729633, DOI: 10.1182/bloodadvances.2017012732.
- Branagan A, Duffy E, Parker T, Seropian S, Foster C, Zhang L, Verma R, Gan G, Zelterman D, Brandt D, Kortmansky J, Witt D, Dhodapkar M. 2168. Journal Of Clinical And Translational Science 2017, 1: 31-32. PMCID: PMC6799516, DOI: 10.1017/cts.2017.118.
- Branagan AR, Duffy E, Albrecht RA, Cooper DL, Seropian S, Parker TL, Gan G, Li F, Zelterman D, Boddupalli CS, Zhang L, Verma R, Ferencz TM, Dhodapkar MV. Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial. Clinical Lymphoma Myeloma & Leukemia 2017, 17: 296-304.e2. PMID: 28343904, PMCID: PMC5413398, DOI: 10.1016/j.clml.2017.02.025.
- Branagan A, Duffy E, Parker T, Seropian S, Foster C, Zhang L, Verma R, Zelterman D, Gan G, Brandt D, Kortmansky J, Witt D, Ferencz T, Dhodapkar M. Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial. Blood 2016, 128: 2139. DOI: 10.1182/blood.v128.22.2139.2139.
- Foss F, Parker T, Li A. Impact of leucovorin on mucositis and skin reactions in pts with peripheral t-cell lymphoma (PTCL) and cutaneous t-cell lymphoma (CTCL) treated with pralatrexate. Journal Of Clinical Oncology 2016, 34: 7558-7558. DOI: 10.1200/jco.2016.34.15_suppl.7558.
- Barmettler S, Nowak RJ, Parker T, Price C. Previously undiagnosed fatal familial haemophagocytic lymphohistiocytosis in a 24-year-old woman. BMJ Case Reports 2016, 2016: bcr2015213698. PMID: 26903364, PMCID: PMC4769444, DOI: 10.1136/bcr-2015-213698.
- Branagan A, Duffy E, Boddupall C, Albrecht R, Zhang L, Verma R, Cooper D, Seropian S, Parker T, Yao X, Ferencz T, Dhodapkar M. Fluzone® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders. Blood 2015, 126: 3058. DOI: 10.1182/blood.v126.23.3058.3058.
- Bar N, Parker TL, Dhodapkar MV. Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart. Journal Of Clinical Oncology 2015, 33: 3689-3690. PMID: 26371139, DOI: 10.1200/jco.2015.63.2224.
- Odell ID, Zeidan AM, Parker TL, Colegio OR, Subtil A. Leukaemic vasculitis with myelodysplastic syndrome. The Lancet 2015, 386: 501-502. PMID: 26251396, DOI: 10.1016/s0140-6736(15)61165-5.
- Brahmandam AS, Brownson K, Skrip L, Parker T, Indes J, Sarac T, Dardik A, Chaar CI. Management of isolated calf vein thrombosis in cancer patients. Vascular 2015, 24: 64-69. PMID: 25957344, DOI: 10.1177/1708538115584726.
- Parker T, Barbarotta L, Foss F. Pralatrexate: treatment of T-cell non-Hodgkins lymphoma. Future Oncology 2012, 9: 21-29. PMID: 23252560, DOI: 10.2217/fon.12.168.
- Parker TL, Cooper DL, Seropian SE, Bolognia JL. Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant. Bone Marrow Transplantation 2012, 48: 646-650. PMID: 23165491, DOI: 10.1038/bmt.2012.218.
- Parker T, Barbarotta L, Girardi M, Foss F. Cutaneous Toxicity Associated with Pralatrexate in Cutaneous and Peripheral T-Cell Lymphoma. Blood 2012, 120: 3660. DOI: 10.1182/blood.v120.21.3660.3660.
- Parker TL, Strout MP. Chronic lymphocytic leukemia: prognostic factors and impact on treatment. Discovery Medicine 2011, 11: 115-23. PMID: 21356166.
- Smilow Multiple Myeloma and Gammopathies ProgramSmilow Cancer Hospital at North Haven6 Devine StreetNorth Haven, CT 06473
- Smilow Multiple Myeloma and Gammopathies ProgramSmilow Cancer Hospital at North Haven6 Devine StreetNorth Haven, CT 06473